NCT02092792 (Clinical Trial/ ANTI-LY6E/ RG7841/ DLYE5953A)

Study Title
A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors NCT02092792

Trial Description
This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and PK of escalating doses of DLYE5953A administered to patients with incurable, locally advanced, or metastatic solid malignancy that has progressed on standard therapy.

The Phase I study consists of two stages: Stage 1 dose-escalation and Stage 2 expansion in selected patients. In Stage 1, a 3 + 3 dose-escalation design will be used to examine the safety, tolerability, and PK of increasing doses of DLYE5953A.

In Stage 2, patients will be enrolled to further characterize the safety, tolerability, and PK of the proposed dose and schedule for future studies.

This trial is sponsored by Genentech®.

Study Data

  • Condition: Neoplasms
  • Interventions:
    • Drugs used in this trial
      • (ANTI-LY6E/ RG7841/ DLYE5953A)
  • Phase: I
  • Enrollment: 42
  • Start: April 2014
  • Estimated Completion: May 2017
  • Last verified: November 2016
  • Last Updated: November 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: November 16, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.